Clinical Trial Update: Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients

View source ↗

Summary

A completed clinical trial evaluated the performance of the NeuMoDx EBV Quant Assay 2.0 in immunocompromised transplant patients with Epstein-Barr virus viremia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• NeuMoDx EBV Quant Assay 2.0 (Epstein-Barr virus DNA quantification assay)

Snippet

Sponsor: QIAGEN Gaithersburg, Inc | Conditions: EBV Viremia | Status: COMPLETED